The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
What is ‘valvular’ atrial fibrillation? A reappraisal
Abstract
Despite the same electrophysiological abnormality, the risk of stroke and systemic embolism in atrial fibrillation (AF) ranges from <1%/year to >20%/year and can be assessed by simple clinical risk factors.1 This has led to the gradual adoption of vitamin K antagonist (VKA) oral anticoagulation as a preventive strategy for most patients with AF, unless clearly identifiable to be at very-low risk.2,3 The recent availability of non-VKA oral anticoagulants (NOACs) is likely to increase the number of AF patients treated with these drugs for stroke prevention in the future. In some such patients, atrial appendage occlusion devices are now also a viable alternative.3 All the pivotal trials comparing VKAs with the NOACs in AF have enrolled patients with so-called ‘non-valvular’ AF and excluded patients at particularly high risk of thrombo-embolism, such as those with AF accompanying mitral stenosis or patients with mechanical prosthetic valves.4 The reasons for not including these patients in trials testing NOACs also included the possibility that the pathogenesis of thrombo-embolism may be substantially different from other types of AF. The distinction between ‘valvular’ AF ‘non-valvular’ AF, however, still remains uncertain, with variable definitions adopted in the NOAC trials. This has led to therapeutic confusion, well illustrated by a recent web-based survey among over 500 Italian physicians mainly involved in the prescription of anticoagulants to AF patients. Here, only 57.1% of the cardiologists and 67.9% of the internists agreed that the existing definitions of non-valvular AF (e.g. from Guidelines) were sufficiently clear.5
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Iung, B. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00201-x · Cited by 3,530
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · cited 1×
“In the AVERROEStrial, testing apixabanvswarfarin inpatients considered ‘unsuitable’ to VKAs, the exclusion criterion was ‘valvular disease requiring surgery’.(53,54) Here, the ‘unsuitability’ to VKAs de facto also excluded mechanical prosthetic valve patients.”
MethodDabigatran versus warfarin in patients with mechanical heart valves
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300615 · Cited by 1,506
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J.-Y., Lowe, J. E., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214876d · Cited by 859
Atrial fibrillation and stroke: new ideas, persisting dilemmas
Halperin, J. L., & Hart, R. G. (1988) · Stroke · doi:10.1161/01.str.19.8.937 · Cited by 231
Cited by
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Self-citationd'Arcy, J. L., Coffey, S., Loudon, M. A., Kennedy, A., Pearson-Stuttard, J., Birks, J., Frangou, E., Farmer, A. J., Mant, D., Wilson, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw229 · Cited by 724
Metadata
- Authors
- De Caterina, R., & Camm, A. J.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-09-29
- Volume
- 35
- Issue
- 47
- Pages
- 3328-3335
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W1974472268
- Cited by
- 164
- References
- 10
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What is ‘valvular’ atrial fibrillation? A reappraisal. https://app.cochat.ai/papers/10.1093/eurheartj/ehu352
- The paper
- De Caterina, R., & Camm, A. J. (2014). What is ‘valvular’ atrial fibrillation? A reappraisal. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu352
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
